Discoveries from the Naviaux Lab




Discoveries from the Naviaux Lab


1.Accelerated Brain Atrophy in Professional Boxers (1983)
2. Monoclonal Antibodies for the Analysis of Natural Genetic Variation (1981-1983)
3. First Infectious Molecular Clones of EMC Virus (1986-1990)


4. The pCL Family of Retroviral Gene Transfer Vectors (1990-1994)
5. Alternative replication pathways for mtDNA and POLG reverse transcriptase activity (1994-1999).
6. Alpers Syndrome and POLG Mitochondrial Disease (1994-2004)
7. Triacetyluridine (TAU) and Pyrimidine Therapy for Mitochondrial Disease (1995-2004)


8. Sand and Ocean Sediment DNA for Molecular Analysis of Modern and Ancient Marine Ecosystems (1998-2005)
9. Reactive Biomolecular Divergences and Biocavity Laser Spectroscopy of Mitochondria During Cell Stress (2003-2006)
10. Purification of the Bicolor Damselfish virus like agent, unpublished (2003-2006)
11. Fourier Transform Ion Cyclotron Resonance (FTICR) Mass Spectrometry for mtDNA Mutation Detection (2006-2007)
12. Exosome Purification for Noninvasive Disease Phenotyping (2007-2015)
13. Mechanisms of Healing and Regeneration in the MRL Mouse (2007-2009)
14. Transgenerational mtDNA Heteroplasmy in the MRL Mouse (2007-2009)
15. Mitochondrial Control of Epigenetics (2008)


16. Oxidative Shielding (2008-2016)
17. The Metabolic Features of the Cell Danger Response (2008-2016)
18. Purinergic and Cell Danger Theories of Autism (2008-2016)
19. Suramin and Antipurinergic Therapies for Autism Spectrum Disorders (2008-Present)
20. Advanced Mass Spec and Metabolomics Platforms (2013-Present)
21. Metabolomics of Chronic Fatigue Syndrome (2015-Present)

2020s in Progress

22. Major depressive disorder and suicide prevention
23. Metabolomics of acute hyperpurinergia and the connection to ASD
24. Purinergic signaling and the anti-aging effects of exercise
25. Metabolomics of Lyme disease
26. Metabolomics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
27. Metabolomic analysis of MELAS, NARP, Kearns-Sayre syndrome, CPEO, and other primary mitochondrial diseases
28. Metabolomics of the childhood vaccine response
29. Newborn dried blood spot metabolomics and exposomics for early diagnosis of autism risk
30. New methods for exposome analysis using newborn dried blood spots
31. Metabolomic analysis of dauer entry and exit in Caenorhabditis elegans
32. Metabolomic predictors of outcomes from parent-child interaction therapy (PCIT) in 3-7 year old children at high risk for neurodevelopmental disorders
33. Metabolomic and exposomic networks in amyotrophic lateral sclerosis (ALS)
34. Environmental monitoring for the prevention of childhood chronic disease
35. Breast milk metabolomics for early diagnosis of childhood neurodevelopmental disorders
36. Purinergic control of cancer DNA instability
37. Metabolomic correlations with magnetoencephalographic (MEG) signatures of PTSD and traumatic brain injury